Rose N F, Marx P A, Luckay A, Nixon D F, Moretto W J, Donahoe S M, Montefiori D, Roberts A, Buonocore L, Rose J K
Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
Cell. 2001 Sep 7;106(5):539-49. doi: 10.1016/s0092-8674(01)00482-2.
We developed an AIDS vaccine based on attenuated VSV vectors expressing env and gag genes and tested it in rhesus monkeys. Boosting was accomplished using vectors with glycoproteins from different VSV serotypes. Animals were challenged with a pathogenic AIDS virus (SHIV89.6P). Control monkeys showed a severe loss of CD4+ T cells and high viral loads, and 7/8 progressed to AIDS with an average time of 148 days. All seven vaccinees were initially infected with SHIV89.6P but have remained healthy for up to 14 months after challenge with low or undetectable viral loads. Protection from AIDS was highly significant (p = 0.001). VSV vectors are promising candidates for human AIDS vaccine trials because they propagate to high titers and can be delivered without injection.
我们研发了一种基于表达env和gag基因的减毒VSV载体的艾滋病疫苗，并在恒河猴身上进行了测试。使用来自不同VSV血清型的糖蛋白载体进行加强免疫。用致病性艾滋病病毒（SHIV89.6P）对动物进行攻击。对照猴子表现出CD4+T细胞严重减少和高病毒载量，8只中有7只进展为艾滋病，平均时间为148天。所有7只接种疫苗的动物最初都感染了SHIV89.6P，但在受到攻击后，病毒载量低或检测不到的情况下，它们保持健康长达14个月。预防艾滋病的效果非常显著（p = 0.001）。VSV载体是人类艾滋病疫苗试验的有希望的候选者，因为它们能繁殖到高滴度，并且无需注射即可递送。
